Patients achieving >90% dose intensity (safety-evaluable population)
| . | CAVALLI phase 2 (N = 206) . | GOYA IPI 2 to 5 (N = 564) . |
|---|---|---|
| Venetoclax | ||
| DI, median (range), % | 95 (4-103) | N/A |
| Patients with >90% DI, n (%) | 123 (61) | N/A |
| Rituximab | ||
| DI, median (range), % | 96 (9-106) | 97 (12-111) |
| Patients with >90% DI, n (%) | 148 (73) | 466 (83) |
| Cyclophosphamide | ||
| DI, median (range), % | 96 (12-128) | 96 (15-110) |
| Patients with >90% DI, n (%) | 148 (73) | 410 (73) |
| Doxorubicin | ||
| DI, median (range), % | 96 (12-128) | 95 (15-110) |
| Patients with >90% DI, n (%) | 148 (73) | 403 (72) |
| Vincristine | ||
| DI, median (range), % | 96 (17-101) | 95 (13-167) |
| Patients with >90% DI, n (%) | 141 (69) | 400 (71) |
| Prednisone | ||
| DI, median (range), % | 97 (10-141) | 96 (3-200) |
| Patients with >90% DI, n (%) | 152 (74) | 425 (75) |
| . | CAVALLI phase 2 (N = 206) . | GOYA IPI 2 to 5 (N = 564) . |
|---|---|---|
| Venetoclax | ||
| DI, median (range), % | 95 (4-103) | N/A |
| Patients with >90% DI, n (%) | 123 (61) | N/A |
| Rituximab | ||
| DI, median (range), % | 96 (9-106) | 97 (12-111) |
| Patients with >90% DI, n (%) | 148 (73) | 466 (83) |
| Cyclophosphamide | ||
| DI, median (range), % | 96 (12-128) | 96 (15-110) |
| Patients with >90% DI, n (%) | 148 (73) | 410 (73) |
| Doxorubicin | ||
| DI, median (range), % | 96 (12-128) | 95 (15-110) |
| Patients with >90% DI, n (%) | 148 (73) | 403 (72) |
| Vincristine | ||
| DI, median (range), % | 96 (17-101) | 95 (13-167) |
| Patients with >90% DI, n (%) | 141 (69) | 400 (71) |
| Prednisone | ||
| DI, median (range), % | 97 (10-141) | 96 (3-200) |
| Patients with >90% DI, n (%) | 152 (74) | 425 (75) |
DI, dose intensity.